China Biologic Products (CBPO) Stock Price, News & Analysis

Company Overview

China Biologic Products Holdings, Inc. engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia. The company also provides human immunoglobulin and IVIG for original and secondary immunoglobulin deficiency, auto-immune deficiency, and immunoglobulin G secondary deficiency; human hepatitis B immunoglobulin for the prevention of measles and contagious hepatitis; human rabies immunoglobulin primarily for passive immunity from bites or claws by rabies or other infected animals; and human tetanus immunoglobulin for the prevention and therapy of tetanus. In addition, it offers placenta polypeptide for the treatment of cell immunity deficiency diseases, viral infection, and leucopenia, as well as assists in postoperative healing; factor VIII for treating coagulopathies; human fibrinogen; and human prothrombin complex concentrate for treating congenital and acquired clotting factor II, VII, IX, X deficiency, as well as excessive anticoagulant, vitamin K deficiency, etc. Further, the company is developing Human fibrinogen for the treatment for lack of fibrinogen and increase human fibrinogen concentration; and artificial dura and spinal dura mater products for use in brain and spinal surgeries. The company sells its products directly, as well as through distributors. The company was formerly known as China Biologic Products, Inc. and changed its name to China Biologic Products Holdings, Inc. in July 2017. China Biologic Products Holdings, Inc. is headquartered in Beijing, the People's Republic of China.

Key Stats

• Today's Range: $117.27 to $120.05
• 50-Day Range: $117.88 to $119.99
• 52-Week Range: $99.74 to $120.05
• Volume: 390,921 shs
• Average Volume: 148,695 shs
• Market Capitalization: $4.72 billion
• P/E Ratio: 33.52
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CBPO Stock Analysis - Frequently Asked Questions

How were China Biologic Products' earnings last quarter?

China Biologic Products Holdings, Inc. (NASDAQ:CBPO) posted its quarterly earnings results on Sunday, March, 28th. The biopharmaceutical company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.69 by $0.22. The biopharmaceutical company earned $112.10 million during the quarter. China Biologic Products had a net margin of 27.43% and a trailing twelve-month return on equity of 8.32%.

What other stocks do shareholders of China Biologic Products own?

Based on aggregate information from My MarketBeat watchlists, some other companies that China Biologic Products investors own include Meta Platforms (META), Bristol Myers Squibb (BMY), NVIDIA (NVDA), Lexicon Pharmaceuticals (LXRX), Gilead Sciences (GILD), Alibaba Group (BABA) and Pfizer (PFE).

Company Calendar

• Last Earnings: 3/28/2021
• Today: 7/07/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological Products, Except Diagnostic
• Sub-Industry: N/A
• Current Symbol: NASDAQ:CBPO
• CIK: 1369868
• Web: www.chinabiologic.com
• Phone: 861065983111
• Fax: N/A
• Employees: 2,269
• Year Founded: 1989

Profitability

• EPS (Trailing Twelve Months): $4.28
• Trailing P/E Ratio: 33.52
• Forward P/E Ratio: 30.93
• P/E Growth: N/A
• Net Income: $138.81 million
• Net Margins: 27.43%
• Pretax Margin: N/A
• Return on Equity: 8.32%
• Return on Assets: 7.64%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 12.01
• Quick Ratio: 10.13

Sales & Book Value

• Annual Sales: $503.70 million
• Price / Sales: 9.38
• Cash Flow: $5.01 per share
• Price / Cash Flow: 23.93
• Book Value: $45.09 per share
• Price / Book: 2.66

Miscellaneous

• Outstanding Shares: 39,360,000
• Free Float: N/A
• Market Cap: $4.72 billion
• Optionable: Optionable
• Beta: 0.47